But I just think it’s too early to be making projections about which is better. I tend to think that RMC-6236 maybe the mother of all RAS inhibitors, but for us to be effective in treating all RAS cancers, we’re probably going to need a whole family of RAS(ON) inhibitors. And that’s why we designed our portfolio the way we did.
Alec Stranahan: Okay. Thanks, and congrats again on the progress.
Mark Goldsmith: Thank you.
Operator: Our next question comes from Ami Fadia with Needham. Your line is now open.
Ami Fadia: Thank you for taking the question and the data. My first question is just around how to interpret the evolution of response with duration of treatment. If I’m reading the chart on Slide 12 correctly, some of the patients who are on the chart are cycle seven, day one on stable disease. But then there are €“ the last two patients in that chart which are cycle five, and they seem to have shown a response rate. I’m just trying to understand, so those clearly were on treatment longer. Is that a fair way to look at it? And overall, is it just too short of a duration for us to really interpret responses over time?
Mark Goldsmith: Well, we definitely need more data, and we need more time on study to collect those data. But you’re right, so that lung cancer patient who shows cycle seven, day one. That means that patient has been on long enough to have likely a third scan. That’s what cycle seven would be €“ cycle seven day one would be a third scan. So that patient, that 40 milligrams, if I’m interpreting this correctly, if we’re talking about the same page, has stable disease with some tumor volume reduction, but not PR. We don’t know if they will go on to shape of PR. We’re not trying to imply that they will or won’t. We don’t know. We’ll have to follow them. So I’ll ask Steve comment on this.
Steve Kelsey: No. I mean €“ I think that you €“ directionally, you are correct and inferring that whether a patient has a response by RECIST is a function of both dose and time on treatment. And clearly, the €“ what this chart is beginning to perhaps indicate is that responses at 40 milligram might be uncommon, which is why we dose escalated to three times that dose level where you are beginning to see RECIST responses if we wait long enough. And as Mark said earlier, we don’t know whether there is a dose at which majority of responses we’ll be seeing the first response evaluation or not. It’s just not as €“ it’s not clear to us whether increasing the dose changes with the assets of response. Again, I want to really €“ I want to reemphasize here that these two diseases are diseases where chemotherapy induces responses, but it doesn’t last very long.
And that’s what we’re trying to solve for. We’re trying to solve for the very short duration of response or benefit the patients get with cytotoxic chemotherapy. The median time to progression for patients with pancreatic cancer that received prior therapy is 3.5 months, and we’re trying to solve for that. So it’s really about what €“ how long it takes the tumor to get to 30% or 31% reduction. It isn’t really the point. The point is how long do they stay on set before they progress again, and we would like to push that beyond 3.5 months.
Ami Fadia: Yes. Okay. That’s helpful. And just clarify for me, after how many cycles is it a patient to receive a scan? Is it every two cycles?
Mark Goldsmith: Every two cycles.
Steve Kelsey: For the first six cycles and then it goes €“ I think it goes to every three months.
Mark Goldsmith: Yes. So cycle three day one means they’ve completed two cycles is the day after they’ve completed two cycles.
